This meta-analysis confirms the role of SGLT2 inhibitors as a key component of therapy in HFpEF, showing robust reductions in the composite of cardiovascular death or heart failure hospitalization—primarily driven by lower heart failure hospitalization rates. Here, SLC5A2 is linked to heart failure.